Porton Pharma Solutions Ltd. (SHE:300363)
China flag China · Delayed Price · Currency is CNY
20.94
-0.89 (-4.08%)
Sep 10, 2026, 3:04 PM CST

Porton Pharma Solutions Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
3,5653,3972,9893,6587,0083,074
Other Revenue
24.0622.9823.119.4426.9931.17
3,5893,4203,0123,6677,0353,105
Revenue Growth
9.39%13.54%-17.87%-47.87%126.55%49.87%
Cost of Revenue
2,4622,4242,3092,2303,3981,843
Gross Profit
1,127995.37702.621,4373,6361,262
Selling, General & Admin
621.51559.38557.81693.17807.66386.63
Research & Development
242.21267.58338.49452.23519.51262.02
Other Operating Expenses
54.8122.110.0535.0958.5414.06
Operating Expenses
938.56867.27926.631,1451,419706.17
Operating Income
188.16128.11-224291.882,218555.88
Interest Expense
-42.32-50.48-62.06-44.15-27.73-21.7
Interest & Investment Income
16.589.0724.0857.8822.8314.31
Currency Exchange Gain (Loss)
-14.36-24.3110.11-20.0150.2510.79
Other Non Operating Income (Expenses)
-4.53-1.37-1.64-2.53-6.73-1.5
EBT Excluding Unusual Items
143.5261.02-253.5283.072,256557.77
Impairment of Goodwill
----40.64--
Gain (Loss) on Sale of Investments
1.336.52-49.24-1.63-8.18-6.79
Gain (Loss) on Sale of Assets
-2.74-1.17-0.770.540.1-3.21
Asset Writedown
-351.43-22.8-92.57-17.49-18.63-16.22
Other Unusual Items
47.7439.1122.0422.7116.2817.28
Pretax Income
-161.5782.68-374.05246.562,246548.83
Income Tax Expense
57.6352.29-8.0671.05309.3873.24
Earnings From Continuing Operations
-219.230.39-365.99175.521,936475.59
Minority Interest in Earnings
64.2865.9578.2491.3468.9948.33
Net Income
-154.9296.34-287.75266.862,005523.92
Net Income to Common
-154.9296.34-287.75266.862,005523.92
Net Income Growth
----86.69%282.78%61.49%
Shares Outstanding (Basic)
538535543545542540
Shares Outstanding (Diluted)
538535543545543540
Shares Change
-0.23%-1.42%-0.31%0.21%0.62%-0.11%
EPS (Basic)
-0.290.18-0.530.493.700.97
EPS (Diluted)
-0.290.18-0.530.493.690.97
EPS Growth
----86.72%280.41%61.67%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
701.79464.45-85.06-500.811,391-296.8
Free Cash Flow Per Share
1.300.87-0.16-0.922.56-0.55
Dividend Per Share
0.0900.090-0.4871.1060.193
Dividend Growth
----55.97%473.06%59.50%
Gross Margin
31.39%29.11%23.33%39.19%51.69%40.64%
Operating Margin
5.24%3.75%-7.44%7.96%31.52%17.90%
Profit Margin
-4.32%2.82%-9.55%7.28%28.51%16.87%
Free Cash Flow Margin
19.55%13.58%-2.82%-13.66%19.78%-9.56%
EBITDA
529.62480.28101.8580.682,452719.86
EBITDA Margin
14.76%14.04%3.38%15.83%34.86%23.18%
D&A For EBITDA
341.47352.17325.8288.8234.54163.98
EBIT
188.16128.11-224291.882,218555.88
EBIT Margin
5.24%3.75%-7.44%7.96%31.52%17.90%
Effective Tax Rate
-63.24%-28.81%13.78%13.35%
Revenue as Reported
3,2513,4203,0123,6677,0353,105